SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 101.78+0.5%Nov 20 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (2651)5/4/2011 3:34:13 PM
From: former_pgs  Read Replies (1) of 3202
 
>So what is the reason for the apparent differential activity? <

As a bit of background, this company was the same one touting that their low affinity EGF-R mAb was advantageous because it did not produce rash.

Of course, the whole point of the rash was that it served as a meaningful indicator of physiological EGF-R inhibition... so, YMI's m.o. of offering lower affinity candidates that have a putative safety advantage lives on.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News